Co-codamol 30/500 wockhardt

Product Overview

Co-codamol 30/500 Wockhardt is a prescription-only combination analgesic tablet produced by Wockhardt, a global pharmaceutical company. The product name indicates the strength of the two active ingredients in each tablet: 30 mg of codeine phosphate and 500 mg of paracetamol. This specific strength is one of several Co-codamol formulations available in the UK.

Active Ingredients

Each tablet contains two active substances:

• Codeine phosphate 30 mg – an opioid analgesic
• Paracetamol 500 mg – a non-opioid analgesic and antipyretic

The combination is formulated to provide analgesic effects through two different mechanisms of action.

Manufacturer Information

Wockhardt UK Ltd is the marketing authorisation holder and manufacturer for this product. Wockhardt is an established pharmaceutical company with manufacturing facilities that operate under Good Manufacturing Practice (GMP) standards. The company supplies a range of generic and branded medicines to the UK market.

Product Formulation

Co-codamol 30/500 Wockhardt is presented as tablets for oral administration. The tablets contain the stated amounts of codeine phosphate and paracetamol as the active ingredients, along with excipients necessary for tablet formation, stability, and bioavailability. The complete list of excipients is detailed in the patient information leaflet supplied with the product.

Legal Classification

This medicine is classified as a Prescription Only Medicine (POM) in the United Kingdom. It can only be obtained with a valid prescription from an authorised prescriber. The prescription-only status reflects the presence of codeine, which is a controlled substance under the Misuse of Drugs Act 1971 (Schedule 2), and the potential risks associated with opioid-containing medicines.

Usage and Administration

Follow the directions provided on the product packaging and the advice of your prescriber. The patient information leaflet included with the medicine contains detailed instructions for use, including how to take the tablets, timing of doses, and maximum daily limits. It is important to read the leaflet before starting treatment and to keep it for future reference.

Important Safety Information

As a prescription medicine containing codeine and paracetamol, this product carries specific warnings and precautions that are detailed in the patient information leaflet and on the packaging. These include, but are not limited to:

• Risk of dependence and tolerance with prolonged use of codeine
• Paracetamol overdose risk if taken with other paracetamol-containing products
• Potential for drowsiness and impaired ability to drive or operate machinery
• Contraindications in certain medical conditions and patient groups
• Interactions with other medicines, including other opioids, sedatives, and certain antidepressants

Your prescriber and pharmacist will assess suitability based on your medical history, current medicines, and individual circumstances.

Storage

Store according to the instructions on the packaging. Typically, medicines should be kept in the original container, out of sight and reach of children, and at the temperature range specified on the label. Do not use after the expiry date printed on the pack.

Supply and Availability

Co-codamol 30/500 Wockhardt is dispensed by pharmacies against a valid NHS or private prescription. Pack sizes and availability may vary. Your pharmacist can advise on current stock and any alternative brands or generic equivalents that may be supplied in accordance with your prescription.

Patient Information Leaflet

A patient information leaflet (PIL) is included with every pack. This leaflet provides comprehensive information on the medicine, including full details of active and inactive ingredients, dosage instructions, warnings, side effects, storage conditions, and what to do if you miss a dose or take too much. Always read the PIL before taking this medicine.

Why This Product May Be Prescribed

Prescribers may select Co-codamol 30/500 Wockhardt when a combination analgesic of this specific strength is clinically appropriate for a patient. The choice of manufacturer (Wockhardt) may be determined by local formulary guidance, availability, or prescribing policy. Patients receiving this product should discuss any questions about their prescription with their doctor or pharmacist.

Regulatory Status

This medicine holds a Marketing Authorisation (MA) granted by the Medicines and Healthcare products Regulatory Agency (MHRA) for the UK market. The MA number, legal category, and other regulatory details are printed on the packaging and in the PIL. Wockhardt is responsible for pharmacovigilance and quality oversight of this product in accordance with UK medicines legislation.